PSY22 - Cost analysis of Voriconazole versus Caspofungin for Primary Therapy of invasive Aspergillosis among High-Risk Hematologic Cancer Patients in China

X Gao,M Xue,J Stephens,Y Chen,S Haider,C Charbonneau

doi:10.1016/j.jval.2015.03.1720

PSY22 - Cost analysis of Voriconazole versus Caspofungin for Primary Therapy of invasive Aspergillosis among High-Risk Hematologic Cancer Patients in China

X Gao, M Xue + Show 4 more

Open Access

https://doi.org/10.1016/j.jval.2015.03.1720

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: May 1, 2015
License type: publisher-specific-oa

Affiliation: Pharmerit (United States), Pfizer (China), Pfizer (United States), Pfizer (France)

#Primary Therapy Of Invasive Aspergillosis #Cancer Patients In China + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

PSY22 - Cost analysis of Voriconazole versus Caspofungin for Primary Therapy of invasive Aspergillosis among High-Risk Hematologic Cancer Patients in China

Full Text